Short Curriculum Vitae: *Katerina Paleologou*

Current Position:	Assistant Professor
Undergraduate Education:	**BSc Hons in Biochemistry with Biomedicine** Biological Sciences, Lancaster University, UK
Post-graduate Education:	• **MSc (by research) in Biomedicine** Biological Sciences, Lancaster University, UK Thesis Project "*Alzheimer's Disease and γ-Secretase Inhibitors*" • **PhD in Biological Sciences** Biological Sciences, Lancaster University, UK Thesis Project "*Inhibitors of α-Synuclein Aggregation as a novel Treatment for Parkinson's disease*" • **Postdoctoral Research Fellow** Laboratory of Molecular Neurobiology and Neuroproteomics (LMNN), *Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland* *Research associated with the elucidation of the role of α-synuclein phosphorylation in Parkinson's disease.*
Areas of Interest	• The physiological function α-synuclein in the brain • The role of amyloid aggregation (α-synuclein & β-amyloid) in neurodegenerative diseases • Identification of α-synuclein aggregation inhibitors
Distinctions	• **Latsis Foundation –Young Investigator Award 2014** *A novel approach to define the role of a-synuclein, the protein that promotes Parkinson's disease, in the cell nucleus* Fubding: 12.000 €
Funding	• **Operational Programme "Competitiveness, Entrepreneurship and Innovation" 2014-2020** *Synthetic biology: from omics technologies to genomic engineering (OMIC-ENGINE)* Total Funding: 4.000.000 € Research group Funding: 480.000 € Member of research group
Representative publications	• N.N. Vaikath, N.K. Majbour, K.E. **Paleologou**, M.T. Ardah, E. van Dam, W.D. van de Berg, S.L. Forrest, L. Parkkinen, W.P. Gai, N. Hattori, M. Takanashi, S.J. Lee, D.M. Mann, Y. Imai, G.M. Halliday, J.Y. Li, O.M. El-

Agnaf. (2015) Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. *Neurobiol. Dis* **79:** 81-99.

- M.K. Mbefo, M.B. Fares, **K.E. Paleologou,** A. Oueslati, G. Yin, S. Tenreiro, M. Pinto, T. Outeiro, M. Zweckstetter, E. Masliah, H.A. Lashuel. (2015) Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and *in vivo*. *J Biological Chemistry* **290:** 9412-9427.
- A. Oueslati, **K.E. Paleologou**, B.L. Schneider, P. Aebischer, H.A. Lashuel. (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. *J Neuroscience* **32:** 1536-1544.
- S. Di Giovanni, S. Eleuteri, **K.E. Paleologou**, G. Yin, M. Zweckstetter, P.A. Carrupt, H.A. Lashuel. (2010) Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. *J Biological Chemistry* **285:** 14941-14954.
- **K.E. Paleologou***, A. Oueslati*, G. Shakked, C.C. Rospigliosi, H.-Y. Kim, G.R. Lamberto, C.O. Fernandez, A. Schmid, F. Chegini, W. P. Gai, D. Chiappe, M. Moniatte, B.L. Schneider, P. Aebischer, D. Eliezer, M. Zweckstetter, E. Masliah, H.A. Lashuel. (2010) Phosphorylation at S87P is enhanced in synucleinopathies, inhibits a-synuclein oligomerisation and influences synuclein-membrane interactions. *J Neuroscience* **30:** 3184-3198. ∗equal contribution
- **K.E. Paleologou***, M.K. Mbefo*, A. Boucharaba, A. Oueslati, D. Olschewski, H. Hirling, and H.A. Lashuel (2010) Phosphorylation of synucleins (α, β and γ) by members of the Polo like family of kinases. *J Biological Chemistry* **285:** 2807-2822. ∗equal contribution
- **K.E. Paleologou**, C.L. Kragh, D.M.A. Mann, S.A. Salem, R. Al-Shami, D.Allsop, A.H. Hassan, P.A. Jensen and O.M.A. El-Agnaf (2009) Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. *Brain*, **132 (Pt 4):** 1093-1101.
- **K.E. Paleologou**, A.W. Schmid, C.C. Rospigliosi, H.Y. Kim, G.R. Lamberto, R.A. Fredenburg, P.T. Lansbury Jr, C.O. Fernandez, D. Eliezer, M. Zweckstetter and H.A. Lashuel (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of α-synuclein. *J Biological Chemistry*, **283:** 16895-16905.
- O.M.A. El-Agnaf, S.A. Salem, **K.E. Paleologou**, A.M. Abogrein, M.D. Curran, O.A. Ross, M.J. Gibson, J.A. and D. Allsop. (2006) Detection of oligomeric forms of α-synuclein protein in cerebrospinal fluid and plasma as a potential biomarker for Parkinson's disease. *FASEB Journal* **18:** 1315-1317.
- O.M.A. El-Agnaf, **K.E. Paleologou**, B. Greer, A.M. Abogrein, J.E. King,

S.A. Salem, N.J. Fullwood, F.E. Benson, R. Hewitt, K.J. Ford, F.L. Martin, P. Harriott , M.R. Cookson and D. Allsop. (2004) A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB Journal, 18: 1315-1317.